Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cogmed is a digital therapeutics company specializing in evidence-based software solutions designed to enhance working memory and attention. Founded as a spin-off from the Karolinska Institute, the company provides a computerized training program that leverages neuroplasticity to improve cognitive functions in individuals with ADHD, brain injuries, and age-related decline. The Cogmed program is widely utilized by healthcare professionals, schools, and clinics worldwide as a non-pharmacological intervention. After being owned by Pearson for a decade, the company returned to independent operations in 2020 to focus on further developing its cognitive training platform. The company's methodology is supported by numerous peer-reviewed studies, making it a leader in the field of cognitive remediation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cogmed.